To evaluate the safety, tolerability, and efficacy of early reinitiation of obesity pharmacotherapy in youth who underwent laparoscopic sleeve gastrectomy (LSG), addressing critical gaps in current treatment protocols.
Key Findings:
93% of youth undergoing LSG were on obesity pharmacotherapy preoperatively but discontinued post-surgery.
62% reported cravings and increased emotional overeating post-surgery.
Early reinitiation of pharmacotherapy is hypothesized to result in greater weight loss (specific percentage needed) and reduced emotional overeating.
Interpretation:
The study suggests that early reinitiation of obesity pharmacotherapy may enhance weight loss and improve emotional eating outcomes without adverse effects on nutritional intake, potentially influencing clinical practice.
Limitations:
Retrospective design may introduce bias.
Lack of standardized protocols for early postoperative pharmacotherapy use.
Potential confounding factors affecting outcomes should be acknowledged.
Conclusion:
Early reinitiation of obesity pharmacotherapy post-LSG may be beneficial for youth, warranting further research to optimize treatment protocols and improve long-term outcomes, emphasizing the urgency of addressing this gap.
